{"id":56898,"date":"2026-02-11T22:06:43","date_gmt":"2026-02-11T14:06:43","guid":{"rendered":"https:\/\/flcube.com\/?p=56898"},"modified":"2026-02-11T22:06:44","modified_gmt":"2026-02-11T14:06:44","slug":"ubrigene-biosciences-partners-with-innovec-biotherapeutics-on-aav-gene-therapy-for-hereditary-eye-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56898","title":{"rendered":"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases"},"content":{"rendered":"\n

uBriGene Biosciences<\/strong>, a China-based advanced therapy medicinal product (ATMP) CDMO<\/strong>, has entered a strategic partnership<\/strong> with Beijing Innovec Biotherapeutics Inc.<\/strong>, a gene therapy company<\/strong>, to jointly advance clinical translation and industrialization of AAV gene therapies<\/strong> for hereditary eye diseases<\/strong>. The collaboration builds on successful IND approvals<\/strong> for Innovec’s IVB103 (China and US)<\/strong> and IVB102 (FDA)<\/strong> projects, with uBriGene providing comprehensive GMP-grade AAV manufacturing and regulatory support<\/strong> for additional pipeline candidates.<\/p>\n\n\n\n

Partnership Structure<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
CDMO Partner<\/strong><\/td>uBriGene Biosciences (ATMP-focused CDMO)<\/td><\/tr>
Gene Therapy Partner<\/strong><\/td>Beijing Innovec Biotherapeutics Inc.<\/td><\/tr>
Therapeutic Focus<\/strong><\/td>Hereditary eye diseases; ophthalmic AAV gene therapy<\/td><\/tr>
Prior Collaboration Success<\/strong><\/td>IVB103 (China + US IND approvals); IVB102 (FDA IND approval)<\/td><\/tr>
Current Scope<\/strong><\/td>Additional AAV candidate + multiple pipeline projects<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Service Portfolio & Technical Capabilities<\/h2>\n\n\n\n
uBriGene Capability<\/th>Innovec Application<\/th>Strategic Value<\/th><\/tr><\/thead>
Process Development<\/strong><\/td>AAV vector optimization for ocular tropism<\/td>Enhanced transduction efficiency and safety<\/td><\/tr>
GMP-Grade AAV Production<\/strong><\/td>Clinical-grade vector manufacturing<\/td>Batch-to-batch consistency; regulatory compliance<\/td><\/tr>
Dual Regulatory Support<\/strong><\/td>China NMPA and US FDA IND submissions<\/td>Accelerated global clinical trial initiation<\/td><\/tr>
Industrialization Platform<\/strong><\/td>Scalable manufacturing for late-stage trials and commercialization<\/td>Cost-efficient supply chain for rare disease indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Market Context<\/h2>\n\n\n\n
Factor<\/th>Industry Analysis<\/th><\/tr><\/thead>
Hereditary Eye Disease Burden<\/strong><\/td>>200 inherited retinal diseases<\/strong> affect millions globally; Leber congenital amaurosis, retinitis pigmentosa<\/strong> lead gene therapy targets<\/td><\/tr>
AAV Ophthalmology Success<\/strong><\/td>Luxturna (Spark\/Roche)<\/strong> validated proof-of-concept; high unmet need<\/strong> for next-generation vectors with improved efficacy and durability<\/td><\/tr>
China CDMO Advantage<\/strong><\/td>uBriGene’s GMP AAV platform<\/strong> offers cost-competitive, high-quality manufacturing<\/strong> vs. US\/EU alternatives; supports domestic and global supply<\/strong><\/td><\/tr>
Innovec Pipeline Expansion<\/strong><\/td>Multiple AAV candidates require consistent manufacturing partner<\/strong>; uBriGene relationship de-risks CMC and regulatory pathways<\/strong><\/td><\/tr>
ATMP Industrialization Gap<\/strong><\/td>Bottleneck in clinical-grade AAV supply<\/strong>; partnership addresses vector manufacturing constraint<\/strong> delaying gene therapy development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development Roadmap<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>Agreement execution; tech transfer for new AAV candidate<\/td>Q1 2026<\/td><\/tr>
Manufacturing<\/strong><\/td>GMP batch production for IND-enabling studies<\/td>2026<\/td><\/tr>
Regulatory<\/strong><\/td>Dual NMPA\/FDA IND submissions<\/td>2026-2027<\/td><\/tr>
Clinical<\/strong><\/td>Phase I\/II initiation for hereditary eye disease indications<\/td>2027<\/td><\/tr>
Expansion<\/strong><\/td>Pipeline project manufacturing scale-up<\/td>Ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding AAV gene therapy clinical translation timelines, GMP manufacturing scale-up success, and regulatory approval pathways for hereditary eye disease treatments. Actual results may differ due to AAV vector immunogenicity challenges, ocular gene therapy durability limitations, and competitive dynamics with established players (Novartis, Roche, Biogen).-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership…<\/p>\n","protected":false},"author":1,"featured_media":56899,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[66,2687,44,1285],"class_list":["post-56898","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-gene-therapy","tag-innovec-biotherapeutics","tag-ophthalmology","tag-ubrigene-biosciences"],"yoast_head":"\nuBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership with Beijing Innovec Biotherapeutics Inc., a gene therapy company, to jointly advance clinical translation and industrialization of AAV gene therapies for hereditary eye diseases. The collaboration builds on successful IND approvals for Innovec's IVB103 (China and US) and IVB102 (FDA) projects, with uBriGene providing comprehensive GMP-grade AAV manufacturing and regulatory support for additional pipeline candidates.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56898\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases\" \/>\n<meta property=\"og:description\" content=\"uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership with Beijing Innovec Biotherapeutics Inc., a gene therapy company, to jointly advance clinical translation and industrialization of AAV gene therapies for hereditary eye diseases. The collaboration builds on successful IND approvals for Innovec's IVB103 (China and US) and IVB102 (FDA) projects, with uBriGene providing comprehensive GMP-grade AAV manufacturing and regulatory support for additional pipeline candidates.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56898\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-11T14:06:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T14:06:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1105.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56898#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56898\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases\",\"datePublished\":\"2026-02-11T14:06:43+00:00\",\"dateModified\":\"2026-02-11T14:06:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56898\"},\"wordCount\":400,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56898#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1105.webp\",\"keywords\":[\"Gene therapy\",\"InnoVec Biotherapeutics\",\"Ophthalmology\",\"uBriGene Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56898#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56898\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56898\",\"name\":\"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56898#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56898#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1105.webp\",\"datePublished\":\"2026-02-11T14:06:43+00:00\",\"dateModified\":\"2026-02-11T14:06:44+00:00\",\"description\":\"uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership with Beijing Innovec Biotherapeutics Inc., a gene therapy company, to jointly advance clinical translation and industrialization of AAV gene therapies for hereditary eye diseases. The collaboration builds on successful IND approvals for Innovec's IVB103 (China and US) and IVB102 (FDA) projects, with uBriGene providing comprehensive GMP-grade AAV manufacturing and regulatory support for additional pipeline candidates.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56898#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56898\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56898#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1105.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1105.webp\",\"width\":1080,\"height\":608,\"caption\":\"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56898#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases - Insight, China's Pharmaceutical Industry","description":"uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership with Beijing Innovec Biotherapeutics Inc., a gene therapy company, to jointly advance clinical translation and industrialization of AAV gene therapies for hereditary eye diseases. The collaboration builds on successful IND approvals for Innovec's IVB103 (China and US) and IVB102 (FDA) projects, with uBriGene providing comprehensive GMP-grade AAV manufacturing and regulatory support for additional pipeline candidates.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56898","og_locale":"en_US","og_type":"article","og_title":"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases","og_description":"uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership with Beijing Innovec Biotherapeutics Inc., a gene therapy company, to jointly advance clinical translation and industrialization of AAV gene therapies for hereditary eye diseases. The collaboration builds on successful IND approvals for Innovec's IVB103 (China and US) and IVB102 (FDA) projects, with uBriGene providing comprehensive GMP-grade AAV manufacturing and regulatory support for additional pipeline candidates.","og_url":"https:\/\/flcube.com\/?p=56898","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-11T14:06:43+00:00","article_modified_time":"2026-02-11T14:06:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1105.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56898#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56898"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases","datePublished":"2026-02-11T14:06:43+00:00","dateModified":"2026-02-11T14:06:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56898"},"wordCount":400,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56898#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1105.webp","keywords":["Gene therapy","InnoVec Biotherapeutics","Ophthalmology","uBriGene Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56898#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56898","url":"https:\/\/flcube.com\/?p=56898","name":"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56898#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56898#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1105.webp","datePublished":"2026-02-11T14:06:43+00:00","dateModified":"2026-02-11T14:06:44+00:00","description":"uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership with Beijing Innovec Biotherapeutics Inc., a gene therapy company, to jointly advance clinical translation and industrialization of AAV gene therapies for hereditary eye diseases. The collaboration builds on successful IND approvals for Innovec's IVB103 (China and US) and IVB102 (FDA) projects, with uBriGene providing comprehensive GMP-grade AAV manufacturing and regulatory support for additional pipeline candidates.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56898#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56898"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56898#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1105.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1105.webp","width":1080,"height":608,"caption":"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56898#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1105.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56898"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56898\/revisions"}],"predecessor-version":[{"id":56900,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56898\/revisions\/56900"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56899"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}